May 18, 2020 — As the research community is generating data from novel research and looking to leverage prior research (e.g., MERS, SARS), there is significant opportunity to integrate these diverse data sources to create an even more valuable data asset for scientific insight generation. This opportunity requires addressing very real data wrangling challenges.
May 14, 2020 — Modern clinical trials distribute samples to an expanding range of screening labs, specialty labs, and bio-banking facilities. Maintaining visibility into sample collection and data processing too often requires manually comparing inventories from each lab’s LIMS, and then checking against what is expected according to the protocol.
May 6, 2020 — Following Scott Marshall’s announcement last week about the QuartzBio team’s COVID-19-Related Data Aggregation Initiative, we wanted to share additional context behind the scope of our efforts. Our initial focus is creating a valuable and thoughtfully constructed data ecosystem, which will result in the ability to draw meaningful context. This is nucleated […]
April 28, 2020 — COVID-19 is at the forefront of many research and development agendas. How can the integration of publicly available data help accelerate these efforts? The QuartzBio team is building and making available a unified SARS-CoV-2 / COVID-19 data ecosystem to support our own work and that of the broader research community. In […]
April 10, 2020 — Just as electronic data capture has become the norm for clinical trial data management, data ecosystems will become the standard for unlocking the full potential of precision medicine. In this brief, learn how biotechs are making data ecosystems a reality, so that they can: Capture information that may be critical to […]
April 1, 2020 — The global pandemic caused by COVID-19 is presenting a public health crisis, and unprecedented challenges in the conduct of clinical trials. The quickly realized disruption has motivated FDA and EMA to issue guidance in direct response. As we continue to adapt to the new reality, we are seeing proactive monitoring of […]
March 19, 2020 — The global pandemic caused by SARS-CoV-2 presents a public health crisis, as well as unprecedented challenges in the conduct of clinical trials. Join us to learn how clinical teams are leveraging technology to quickly and efficiently gain visibility into their clinical samples across sites, labs, and storage facilities.
March 10, 2020 — In the years to come, public data will play an increasingly important role in drug discovery and development. In this brief, learn how biotechs are strategically using publicly available data to: Accelerate their path to the clinic by circumventing time-consuming, expensive data generation Increase the likelihood of success by mitigating the […]
February 4, 2019 — Pharmaceutical and healthcare organizations have zettabytes of data at their disposal, literally. They have spent the last decade accumulating information from electronic health records, insurance claims, lab results and more. Whatever frustrations one might have with the industry at large, it can’t reasonably be suggested that companies were caught unaware by […]
January 15, 2020 — With public data set to play an increasingly important role in drug discovery and development, an integrated, data-driven approach to clinical planning can optimize the probability of success. The increasing availability of public data sets, such as The Cancer Genome Atlas (TCGA) and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), offers a […]
